Hubbry Logo
Alpha-adrenergic agonistAlpha-adrenergic agonistMain
Open search
Alpha-adrenergic agonist
Community hub
Alpha-adrenergic agonist
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Alpha-adrenergic agonist
Alpha-adrenergic agonist
Alpha-adrenergic agonist
View on Wikipedia
from Wikipedia

Alpha adrenergic agonist
Drug class
Phenylephrine
Skeletal structor formula of phenylephrine, a common nasal decongestant
Class identifiers
UseDecongestant, Hypotension, Bradycardia, Hypothermia etc.
ATC codeN07
Biological targetAlpha adrenergic receptors of the α subtype
External links
MeSHD000316
Legal status
In Wikidata

Alpha-adrenergic agonists are a class of sympathomimetic agents that selectively stimulate alpha adrenergic receptors. The alpha-adrenergic receptor has two subclasses, α1 and α2. Alpha 2 receptors are associated with sympatholytic properties. Alpha-adrenergic agonists have the opposite function of alpha blockers. Alpha adrenoreceptor ligands mimic the action of epinephrine and norepinephrine signaling in the heart, smooth muscle and central nervous system, with norepinephrine being the highest affinity. The activation of α1 stimulates the membrane bound enzyme phospholipase C, and activation of α2 inhibits the enzyme adenylate cyclase. Inactivation of adenylate cyclase in turn leads to the inactivation of the secondary messenger cyclic adenosine monophosphate and induces smooth muscle and blood vessel constriction.

Classes

[edit]
Norepinephrine (noradrenaline)

Although complete selectivity between receptor agonism is rarely achieved, some agents have partial selectivity. NB: the inclusion of a drug in each category just indicates the activity of the drug at that receptor, not necessarily the selectivity of the drug (unless otherwise noted).

α1 agonist

[edit]
Main article: Alpha-1 adrenergic receptor § agonist

α1 agonist: stimulates phospholipase C activity. (vasoconstriction and mydriasis; used as vasopressors, nasal decongestants and during eye exams). Selected examples are:

α2 agonist

[edit]
Main article: Alpha-2 adrenergic receptor § Agonists

α2 agonist: inhibits adenylyl cyclase activity, reduces brainstem vasomotor center-mediated CNS activation; used as antihypertensive, sedative & treatment of opiate dependence and alcohol withdrawal symptoms). Selected examples are:

Nonspecific agonist

[edit]

Nonspecific agonists act as agonists at both alpha-1 and alpha-2 receptors.

Undetermined/unsorted

[edit]

The following agents are also listed as agonists by MeSH.[18]

Clinical significance

[edit]

Alpha-adrenergic agonists, more specifically the auto receptors of alpha 2 neurons, are used in the treatment of glaucoma by decreasing the production of aqueous fluid by the ciliary bodies of the eye and also by increasing uveoscleral outflow. Medications such as clonidine and dexmedetomidine target pre-synaptic auto receptors, therefore leading to an overall decrease in norepinephrine which clinically can cause effects such as sedation, analgesia, lowering of blood pressure and bradycardia. There is also low quality evidence that they can reduce shivering post operatively.[19]

The reduction of the stress response caused by alpha 2 agonists were theorised to be beneficial peri operatively by reducing cardiac complications, however this has shown not to be clinically effective as there was no reduction in cardiac events or mortality but there was an increased incidence of hypotension and bradycardia.[20]

Alpha-2 adrenergic agonists are sometimes prescribed alone or in combination with stimulants to treat ADHD.[21]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Alpha-adrenergic agonist

View on Grokipedia
from Grokipedia
Alpha-adrenergic agonists are a class of pharmacological agents that selectively stimulate alpha-adrenergic receptors, which are G-protein-coupled receptors activated by catecholamines such as norepinephrine and epinephrine in the , resulting in effects like , , and . These drugs are subdivided into alpha-1 and alpha-2 agonists based on receptor specificity, with alpha-1 agonists primarily causing peripheral and increased , while alpha-2 agonists often exert central effects including reduced sympathetic outflow and analgesia. They are widely used in clinical settings for managing conditions such as , , , , attention-deficit/hyperactivity disorder (ADHD), and procedural . Alpha-1 adrenergic agonists bind to alpha-1 receptors, which are coupled to the protein, activating to produce inositol triphosphate (IP3) and diacylglycerol (DAG), thereby increasing intracellular calcium and inducing contraction in vascular beds. Common examples include , used as a vasopressor for in and as a nasal , and for . These agents are contraindicated in conditions like severe or due to risks of excessive leading to reduced organ and potential cardiac strain. In contrast, alpha-2 adrenergic agonists target alpha-2 receptors coupled to the Gi protein, inhibiting and decreasing cyclic AMP levels, which hyperpolarizes neurons and modulates release to produce , analgesia, and effects. Key drugs like are employed for and ADHD by reducing central sympathetic activity, while serves as an ICU with minimal respiratory depression, decreasing and requirements by 40–75%. Adverse effects for alpha-2 agonists include , , and dry mouth, though they offer advantages in preserving arousability during compared to traditional agents.

Background and Definition

Definition and Overview

Alpha-adrenergic agonists are a class of drugs or endogenous substances that selectively bind to and activate alpha-adrenergic receptors, mimicking the physiological effects of the catecholamines norepinephrine and epinephrine on the sympathetic nervous system. These agents are sympathomimetics, meaning they imitate the actions of sympathetic neurotransmitters to produce responses such as enhanced vascular tone and smooth muscle contraction. Adrenergic receptors, including the alpha subtypes, belong to the superfamily of G-protein-coupled receptors that transduce signals from extracellular ligands to intracellular pathways. The historical development of alpha-adrenergic agonists traces back to early 20th-century studies on sympathomimetic amines, with key compounds like and identified for their ability to stimulate sympathetic responses around 1910. A pivotal advancement occurred in 1948 when pharmacologist Raymond Ahlquist differentiated alpha and beta adrenergic receptors based on the potency order of sympathomimetic agents, laying the groundwork for selective agonist development. This classification was supported by the 1946 isolation of norepinephrine as the primary sympathetic neurotransmitter by Ulf von Euler, confirming its role in alpha receptor activation. In general, alpha-adrenergic agonists amplify activity, leading to effects like , elevated , and contraction of smooth muscles in various tissues. These agents primarily include direct-acting compounds that bind directly to alpha receptors, such as , for their specificity to alpha-mediated responses. Indirect-acting sympathomimetics promote catecholamine release and can produce alpha effects but affect multiple receptor types.

Adrenergic Receptor Basics

Adrenergic receptors constitute a family of G protein-coupled receptors (GPCRs) that are primarily responsive to the endogenous catecholamines norepinephrine and epinephrine. These receptors transduce signals from these ligands through interactions with heterotrimeric G proteins, initiating intracellular cascades that modulate cellular functions. In the , adrenergic receptors play a central role in mediating the , a physiological to stress that prepares the body for immediate action. They are broadly classified into alpha and beta subtypes, reflecting differences in their signaling pathways and tissue-specific roles. Adrenergic receptors are widely distributed across various tissues, including vascular where they regulate , the (CNS) influencing neuronal excitability, and peripheral tissues such as the heart and lungs. The primary endogenous is norepinephrine, released by postganglionic sympathetic neurons, while epinephrine, secreted by the , serves as a circulating with binding affinities that enable systemic effects. Alpha-adrenergic agonists act as exogenous activators of these receptors, mimicking the binding of catecholamines to elicit targeted responses.

Receptor Subtypes and Classification

α1-Adrenergic Receptors

α1-Adrenergic receptors are a subclass of G protein-coupled receptors (GPCRs) characterized by seven transmembrane domains, forming a structure typical of the rhodopsin-like family of GPCRs. These receptors couple primarily to the protein subtype, which facilitates their activation of downstream signaling pathways. The three main subtypes—α1A, α1B, and α1D—exhibit distinct pharmacological profiles and tissue distributions, identified through and functional studies in the . These receptors are predominantly located postsynaptically in various tissues, including vascular smooth muscle, the heart, central nervous system (CNS), and genitourinary tract. The α1A subtype is notably expressed in the prostate and certain brain regions, α1B in the liver and heart, and α1D in large blood vessels such as the aorta. In the eye, α1 receptors are found on the radial muscle of the iris, while in the genitourinary system, they are present in structures involved in reproductive functions. Upon activation by endogenous ligands like norepinephrine and epinephrine, α1-adrenergic receptors stimulate (PLC), leading to the hydrolysis of (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 then binds to receptors on the , triggering the release of calcium ions (Ca²⁺) from intracellular stores, which mediates various physiological responses. This signaling cascade underpins key functions such as in vascular to regulate , mydriasis via contraction of the iris dilator muscle to increase size, and facilitation of through contraction in the genitourinary tract.

α2-Adrenergic Receptors

α2-Adrenergic receptors (α2-ARs) are a subclass of adrenergic receptors belonging to the (GPCR) superfamily, characterized by seven transmembrane domains that facilitate ligand binding and . They are primarily coupled to the inhibitory (Gi/o), which mediates their downstream effects. There are three main pharmacological subtypes in humans: α2A, α2B, and α2C, each encoded by distinct genes (ADRA2A, ADRA2B, and ADRA2C, respectively) and exhibiting varying affinities for endogenous ligands like norepinephrine and epinephrine. These receptors are predominantly located presynaptically on adrenergic neurons, where they function as autoreceptors to regulate neurotransmitter release, but they are also expressed postsynaptically in various tissues. In the central nervous system (CNS), α2-ARs are abundant in regions such as the locus coeruleus, cerebral cortex, and spinal cord, with the α2A subtype being particularly prevalent postsynaptically in the prefrontal cortex. Peripherally, they are found in the pancreas (especially on β-cells), platelets, vascular smooth muscle, kidney, heart, and gastrointestinal tract, contributing to diverse regulatory roles. Upon activation by endogenous catecholamines, α2-ARs inhibit activity through Gi/o protein coupling, leading to decreased intracellular (cAMP) levels and subsequent modulation of ion channels and protein kinases. This signaling cascade primarily results in the inhibition of release from presynaptic terminals, providing a key mechanism for autoregulation. The physiological roles of α2-ARs include inhibition of norepinephrine release from sympathetic neurons, which helps maintain during sympathetic activation. In the CNS, they contribute to via α2A-mediated suppression of noradrenergic activity in the and analgesia through postsynaptic inhibition in spinal pathways. Peripherally and centrally, activation promotes by enhancing parasympathetic tone and reducing sympathetic outflow.

Mechanism of Action

Molecular Binding

Alpha-adrenergic agonists bind to the orthosteric site of α-adrenergic receptors, which are G protein-coupled receptors (GPCRs) embedded in the , primarily interacting with residues in the transmembrane helices (TMs) 3, 5, 6, and 7, as well as extracellular loops (ECLs) such as ECL2. This binding involves key interactions like hydrogen bonds and salt bridges with conserved aspartate residues (e.g., D106^{3.32} in α_{1A} or D128^{3.32} in α_{2A}) and serine or residues (e.g., S188^{5.42} or S215^{5.42}), alongside hydrophobic and π-π stacking contacts that position the agonist within the pocket. Upon binding, the agonist stabilizes the active receptor conformation by inducing an outward displacement of TM6 (approximately 12-14 ) and adjustments in TM7, which disrupts ionic locks in motifs like DRY and enables coupling, as observed in cryo-EM structures of agonist-bound α_{1A} and α_{2A} receptors. A 2024 cryo-EM study at 2.8 resolution revealed that epinephrine adopts a unique binding conformation in the α_{2A}-AR–G_i complex, with its β-carbon hydroxyl group oriented extracellularly and N-methyl group toward TM7 (F427^{7.38}), forming hydrogen bonds with D128^{3.32}, Y431^{7.42}, S215^{5.43}, and S219^{5.46}, highlighting subtype-specific recognition distinct from β-adrenergic receptors. The affinity of an alpha-adrenergic agonist refers to its binding strength to the receptor, often quantified by the (K_d), while describes the ability to activate the receptor and produce a maximal response (E_max). Potency, measured by the half-maximal effective concentration (EC_{50}), indicates the concentration required for 50% of the maximal effect and distinguishes agonists from antagonists, which bind but do not activate; full agonists like norepinephrine achieve E_max, whereas partial agonists like elicit a submaximal response even at saturating concentrations due to incomplete conformational stabilization. These properties vary by subtype, with norepinephrine showing high affinity (low EC_{50}) for both α_1 and α_2 receptors through its catecholamine interactions. Selectivity for α_1 versus α_2 subtypes arises from structural features of the agonists and receptor pockets; most alpha-adrenergic agonists share a backbone, as in endogenous catecholamines like norepinephrine, which facilitates polar interactions in the orthosteric site. For enhanced α_2 selectivity, agonists like incorporate an or ring, enabling specific π-π stacking with residues such as Y409^{6.55} in α_{2A}, which differentiates binding from α_1 subtypes lacking this optimal aromatic cage. Subtype-specific residues, such as M292^{6.55} in α_{1A} versus aromatic clusters in α_{2A}, further modulate these interactions to favor selective . The relationship between agonist concentration and receptor response is commonly modeled by the Hill equation, which accounts for and describes the dose-response curve: E=Emax⁡[A]nEC50n+[A]nE = E_{\max} \frac{[A]^n}{EC_{50}^n + [A]^n} where EE is the observed effect, Emax⁡E_{\max} is the maximum effect, [A][A] is the concentration, EC50EC_{50} is the concentration for half-maximal effect, and nn is the Hill coefficient indicating (typically near 1 for non- in GPCRs). This equation provides a framework for quantifying potency and efficacy in binding studies, with EC_{50} values derived from fitted curves reflecting the molecular interactions at the receptor.

Physiological Effects

Alpha-adrenergic agonists elicit a range of physiological effects by stimulating α1 and α2 receptor subtypes, which are G-protein-coupled receptors primarily responsive to catecholamines like norepinephrine and epinephrine. These effects span multiple organ systems, reflecting the widespread distribution of adrenergic receptors in the body. In the cardiovascular system, activation of peripheral α1-adrenergic receptors on vascular induces , thereby elevating systemic vascular resistance and . Conversely, stimulation of central α2-adrenergic receptors in the reduces sympathetic outflow, leading to decreased and further modulation of through on catecholamine release. Ocular effects primarily involve α1-adrenergic receptor activation in the radial dilator muscle of the iris, resulting in or pupil dilation, which facilitates light entry and visual accommodation adjustments. Within the , α2-adrenergic agonists promote sedation and analgesia by inhibiting neuronal firing in areas such as the , thereby dampening noradrenergic transmission and enhancing inhibitory pathways. In contrast, α1-adrenergic receptor stimulation contributes to states by enhancing excitatory neurotransmission in regions like the ventral , increasing vigilance and promoting activity. Effects on other systems include α2-mediated relaxation of gastrointestinal , which inhibits motility and secretory activity through presynaptic inhibition of release. α1-adrenergic activation in uterine induces contraction, increasing myometrial tone via calcium-dependent signaling pathways. Additionally, α2-adrenergic receptors on platelets facilitate aggregation in response to catecholamines, supporting hemostatic responses by enhancing platelet reactivity.

Pharmacological Properties

Pharmacokinetics

Alpha-adrenergic agonists exhibit variable absorption depending on the and specific agent. is common for agents like and , with demonstrating nearly complete of approximately 93% due to rapid hydrolysis to its desglymidodrine. In contrast, recent studies indicate that oral has negligible systemic (less than 0.01%) due to extensive presystemic via sulfation in the gut wall and liver, rendering it ineffective as an oral nasal . As of November 2024, the FDA has proposed removing oral from over-the-counter monograph conditions for nasal decongestion based on this pharmacokinetic profile. Intravenous routes, as used for and epinephrine, provide complete , while of provides rapid local onset with minimal systemic absorption, and intranasal yields rapid onset with of approximately 40-80%. Overall, across the class ranges from negligible to 90%, influenced by first-pass effects and formulation. Distribution of alpha-adrenergic agonists is characterized by their , which determines tissue penetration. Lipophilic agents such as and readily cross the blood-brain barrier, enabling effects, with showing a rapid distribution of about 6 minutes in a two-compartment model. is generally moderate, ranging from 20% to 50%; for example, binds 20-40% to , while has low binding (data limited). These properties facilitate distribution to vascular and other target tissues, with typically 2-4 L/kg for most agents in the class. Metabolism of alpha-adrenergic agonists primarily occurs in the liver, involving enzymes or conjugation pathways, leading to half-lives of 1 to 12 hours. undergoes extensive presystemic sulfation and hepatic metabolism independent of CYP enzymes, resulting in a short of 2-3 hours after intravenous administration. is partially metabolized by to inactive metabolites, with an elimination of 12-16 hours. is a rapidly converted to desglymidodrine via enzymatic , which has a of 3-4 hours, while is metabolized via and direct , with a of approximately 2 hours. Excretion is predominantly renal for the class, with clearance rates varying widely, typically 200-2100 mL/min depending on the agent. is primarily eliminated unchanged in the via renal , accounting for over 80% of the dose. elimination involves 40-60% renal excretion of unchanged drug and metabolites, with the remainder via feces. Similarly, desglymidodrine from is excreted renally at about 80%, and dexmedetomidine shows 80-90% urinary elimination. These pharmacokinetic profiles inform dosing intervals, often requiring adjustments in renal impairment to avoid accumulation.

Pharmacodynamics

Alpha-adrenergic agonists exert their effects through dose-dependent interactions with α1 and α2 adrenergic receptors, influencing receptor occupancy and subsequent physiological responses. The fraction of receptors occupied by an , which correlates with the magnitude of the response, follows the standard binding equation: θ=[A]Kd+[A]\theta = \frac{[A]}{K_d + [A]} where θ\theta represents the fractional occupancy, [A][A] is the agonist concentration, and KdK_d is the . This model underpins the pharmacodynamic relationship between concentration and receptor activation for both subtypes, with pharmacokinetic factors briefly affecting the timing of peak occupancy. α1-selective agonists like demonstrate high potency and vascular affinity, primarily activating postsynaptic Gq-coupled α1 receptors to trigger phospholipase C-mediated calcium release and contraction. Their effects exhibit dose-dependence, with thresholds occurring at low concentrations (e.g., immediate increases starting from minimal doses in vascular models), escalating to pronounced systemic as doses rise. In contrast, α2 agonists such as display selectivity ratios of approximately 200:1 for α2 over α1 receptors, enabling presynaptic inhibition of norepinephrine release via Gi/o protein coupling, which reduces cyclic AMP and neuronal firing. Subtype-specific dynamics further differentiate responses: α2 agonists like and (with even higher selectivity, ~1620:1) show dose-dependent effects, such as , emerging at higher concentrations that achieve sufficient blood-brain barrier penetration (e.g., 2–4 mcg/kg for ). Chronic administration of these agents leads to tolerance, particularly pronounced with α2 agonists, through mechanisms including receptor downregulation and homologous desensitization, as evidenced by reduced in prolonged exposure models. This tolerance manifests as diminished responsiveness, with withdrawal potentially reversing inhibitory effects due to adaptive changes in receptor density and signaling.

Clinical Applications

Uses of α1 Agonists

α1-adrenergic agonists are primarily employed in clinical settings to induce , thereby addressing conditions involving and localized vascular dilation. Intravenous is commonly administered for the management of acute , such as that induced by spinal or vasodilatory states, where it rapidly elevates through peripheral arterial . In septic shock, norepinephrine serves as the first-line vasopressor, recommended by guidelines for restoring in patients with refractory despite fluid . Midodrine, an oral converted to the active α1 desglymidodrine, is used to treat by increasing vascular tone and blood pressure, particularly in patients with autonomic dysfunction. Topical α1 play a key role in treating associated with or upper respiratory infections. Oxymetazoline, applied as a , provides symptomatic relief by constricting blood vessels in the , but its use is limited to short-term application (typically 3 days) to prevent rebound congestion. Similarly, intranasal offers effects for temporary relief of nasal discomfort due to colds, allergies, or sinus pressure, though oral formulations have been deemed ineffective by regulatory review. In , α1 agonists contribute to both diagnostic and therapeutic applications. , a relatively selective α2-adrenergic agonist, is used as adjunctive (0.5% solution) in open-angle glaucoma to reduce by decreasing aqueous humor production, particularly in patients on maximally tolerated therapy. ophthalmic drops (1-10%) are employed to induce during eye examinations or procedures, facilitating dilation for better visualization of ocular structures. Additionally, may serve as an adjunct vasopressor in management when combined with other agents.

Uses of α2 Agonists

α₂-adrenergic agonists primarily exert their therapeutic effects through mechanisms, reducing sympathetic outflow and norepinephrine release, which distinguishes their applications from peripheral actions. In the , oral serves as a centrally acting agent that lowers by stimulating α₂ receptors in the , thereby decreasing activity and reducing . This approach is particularly useful for patients with resistant or those requiring step-down therapy from more potent agents. Clinical studies have demonstrated its efficacy in achieving significant reductions, with typical dosing starting at 0.1 mg twice daily. For and , is widely employed in intensive care units and procedural settings due to its selective α₂ , which promotes and analgesia without causing significant respiratory depression. It reduces the need for opioids by 50-75% and benzodiazepines by up to 80% during , facilitating lighter levels and easier weaning from ventilators. In pediatric patients, it has been shown to prevent , reducing incidence from 60% to 26% in certain procedures. Lofexidine is approved for mitigating symptoms of by inhibiting noradrenergic hyperactivity in the , a key brain region involved in withdrawal manifestations such as anxiety, sweating, and gastrointestinal distress. As an α₂ with fewer hypotensive effects than , it allows for outpatient management, with clinical trials showing superior tolerability and equivalent efficacy in symptom reduction compared to over 5-7 days of treatment. Clonidine also finds application in attention-deficit/hyperactivity disorder (ADHD), particularly via transdermal patches that provide steady-state delivery to improve attention and reduce hyperactivity in pediatric patients through prefrontal cortex modulation. Guanfacine, another selective α2 agonist, is approved for ADHD treatment in children and adolescents, often as monotherapy or adjunct to stimulants, by enhancing prefrontal cortical function. Extended-release formulations have demonstrated symptom improvement in 8-week trials, often as an adjunct to stimulants for those with comorbid sleep issues. Additionally, clonidine serves as an adjunct in neuropathic pain management by spinal α₂ receptor activation, inhibiting nociceptive transmission and enhancing opioid analgesia in chronic conditions like diabetic neuropathy.

Safety and Considerations

Adverse Effects

Alpha-adrenergic agonists can produce adverse effects that stem from their physiological impacts on vascular tone, cardiac function, and activity. Stimulation of α1 receptors leads to , which commonly results in due to activation in response to elevated . Hypertensive crises may occur from excessive systemic , particularly with rapid or high-dose administration. is a frequent complaint, arising from cerebral and associated with toxicity in agents like . Piloerection, or gooseflesh, results from contraction of the arrector pili muscles via α1-mediated sympathetic activation and is reported in up to 13% of users of drugs such as . Central α2 receptor activation often causes dry mouth () through reduced secretion, affecting a significant portion of patients on . and are prevalent, stemming from decreased noradrenergic outflow in the , with somnolence reported in clinical trials of and . Abrupt withdrawal can precipitate due to sudden sympathetic hyperactivity, sometimes exceeding pretreatment levels. Depression is a rare but documented effect with chronic use, potentially linked to altered monoamine transmission. and may also occur, particularly with higher doses, reflecting reduced sympathetic tone.

General Adverse Effects

Alpha-adrenergic agonists may contribute to cardiac arrhythmias by potentiating arrhythmogenic triggers or altering , particularly in patients with underlying cardiac conditions. Intravenous administration risks tissue necrosis or sloughing from , as seen with , due to localized compromising . Tolerance develops with prolonged use, leading to diminished efficacy and potential dose escalation, as observed in vascular responses to both α1 and α2 agonists.

Contraindications and Interactions

Alpha-adrenergic agonists are contraindicated in patients with known to the specific agent or class, as this can lead to severe allergic reactions including . For α1-adrenergic agonists, absolute contraindications include severe coronary or , where vasoconstrictive effects may exacerbate ischemia or infarction; narrow-angle , due to potential increases in ; and , particularly within two weeks of (MAOI) use, as this heightens risks of . Additionally, these agents are contraindicated in urine retention; relative contraindications include peripheral vascular or mesenteric , where further vasoconstriction could worsen tissue . In the case of α2-adrenergic agonists such as , absolute contraindications are fewer, but abrupt discontinuation poses a significant risk of rebound and withdrawal symptoms including and agitation; thus, these agents should not be initiated or managed without a plan to avoid sudden cessation in dependent patients. Relative contraindications for α1-adrenergic agonists encompass , , prostatic , and Raynaud's , where the pressor effects may intensify underlying vascular or cardiac strain. For α2-adrenergic agonists, relative contraindications include preexisting , , renal impairment, and advanced age, as these patients are prone to excessive , , or falls. Significant drug interactions occur with MAOIs, where concurrent use of α-adrenergic agonists—particularly indirect-acting ones like decongestants—can precipitate a due to enhanced catecholamine release and sympathomimetic potentiation. Combination with beta-blockers may result in unopposed α-adrenergic stimulation, leading to paradoxical and , necessitating careful or avoidance. Tricyclic antidepressants can antagonize α2-adrenergic receptors, reducing the efficacy of α2 agonists like and potentially causing loss of control or withdrawal-like symptoms. Regarding pregnancy, under the current FDA Pregnancy and Lactation Labeling Rule (PLLR), use requires weighing potential benefits against s, with limited human data available for most agents. For , animal studies show no fetal , but there are inadequate well-controlled studies in humans; it crosses the , and neonatal monitoring is advised. and may cause fetal harm due to vasoconstrictive effects reducing uterine blood flow and are generally avoided, especially in the first trimester. Brimonidine and have no evidence of in animal studies, though human data are limited; is often used for in . These agents should generally be avoided during labor, as α1 stimulation may impair fetal oxygenation. Clinical use requires vigilant monitoring, including continuous electrocardiogram (ECG) assessment for arrhythmias or ischemic changes in patients with cardiac risk factors, and gradual titration to prevent hypertensive overshoot or .

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK534230/
  2. https://www.ncbi.nlm.nih.gov/books/NBK551698/
  3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389556/
  4. https://cvpharmacology.com/vasoconstrictor/alpha-agonist
  5. https://www.sciencedirect.com/topics/medicine-and-dentistry/adrenergic-receptor
  6. https://www.sciencedirect.com/topics/neuroscience/sympathomimetic-amines
  7. https://www.sciencedirect.com/topics/neuroscience/alpha-adrenergic-receptor
  8. https://www.ncbi.nlm.nih.gov/books/NBK540977/
  9. https://www.ncbi.nlm.nih.gov/books/NBK507716/
  10. https://med.libretexts.org/Bookshelves/Anatomy_and_Physiology/Anatomy_and_Physiology_%28Boundless%29/14%253A_Autonomic_Nervous_System/14.4%253A_Neurotransmitters_and_Receptors/14.4B%253A_Adrenergic_Neurons_and_Receptors
  11. https://www.guidetopharmacology.org/GRAC/FamilyIntroductionForward?familyId=4
  12. https://www.ncbi.nlm.nih.gov/books/NBK539845/
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC8301793/
  14. https://www.ccjm.org/content/ccjom/57/5/481.full.pdf
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC2034198/
  16. https://www.ncbi.nlm.nih.gov/books/NBK542195/
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC3252969/
  18. https://pmc.ncbi.nlm.nih.gov/articles/PMC9885157/
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC10282093/
  20. https://www.science.org/doi/10.1126/sciadv.abj5347
  21. https://www.nature.com/articles/s12276-024-01296-x
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC2816740/
  23. https://www.ncbi.nlm.nih.gov/books/NBK500023/
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC2913435/
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC4389556/
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC6326840/
  27. https://pubmed.ncbi.nlm.nih.gov/6132991/
  28. https://pubmed.ncbi.nlm.nih.gov/16699075/
  29. https://pubmed.ncbi.nlm.nih.gov/34707/
  30. https://go.drugbank.com/drugs/DB00211
  31. https://www.fda.gov/news-events/press-announcements/fda-proposes-ending-use-oral-phenylephrine-otc-monograph-nasal-decongestant-active-ingredient-after
  32. https://www.ncbi.nlm.nih.gov/books/NBK534801/
  33. https://pubmed.ncbi.nlm.nih.gov/21318594/
  34. https://go.drugbank.com/drugs/DB00575
  35. https://www.ncbi.nlm.nih.gov/books/NBK459124/
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC10755021/
  37. https://www.jstage.jst.go.jp/article/tjem1920/150/2/150_2_145/_pdf
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC2724647/
  39. https://www.sccm.org/clinical-resources/guidelines/guidelines/surviving-sepsis-guidelines-2021
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC7963440/
  41. https://www.mayoclinic.org/drugs-supplements/apraclonidine-ophthalmic-route/description/drg-20062024
  42. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020258s026lbl.pdf
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC6968526/
  44. https://pmc.ncbi.nlm.nih.gov/articles/PMC5322220/
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC4847524/
  46. https://pubmed.ncbi.nlm.nih.gov/2894150/
  47. https://www.mayoclinic.org/drugs-supplements/clonidine-oral-route/description/drg-20063252
  48. https://pubmed.ncbi.nlm.nih.gov/14985068/
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC443234/
  50. https://pubmed.ncbi.nlm.nih.gov/6150108/
  51. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/alpha-adrenergic-receptor
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC9680847/
  53. https://www.osmosis.org/learn/Alpha-2_adrenergic_agonists:_Nursing_Pharmacology
  54. https://pmc.ncbi.nlm.nih.gov/articles/PMC4150853/
  55. https://www.fda.gov/drugs/labeling-information-drug-products/pregnancy-and-lactation-labeling-resources
  56. https://www.drugs.com/pregnancy/clonidine.html
  57. https://www.drugs.com/pregnancy/phenylephrine.html
  58. https://www.ncbi.nlm.nih.gov/books/NBK501922/
Add your contribution
Related Hubs
User Avatar
No comments yet.